Literature DB >> 32335433

Maternal occupational exposure to polycyclic aromatic hydrocarbons and the risk of isolated congenital heart defects among offspring.

Jenil Patel1, Wendy N Nembhard2, Maria D Politis2, Carissa M Rocheleau3, Peter H Langlois4, Gary M Shaw5, Paul A Romitti6, Suzanne M Gilboa7, Tania A Desrosiers8, Tabassum Insaf9, Philip J Lupo10.   

Abstract

BACKGROUND: Although there is evidence in experimental model systems that exposure to polycyclic aromatic hydrocarbons (PAHs) is linked with congenital heart defects (CHDs), few studies have examined the association in humans. We conducted a case-control study to examine the association between maternal exposure to PAHs and CHDs in offspring using data from the National Birth Defects Prevention Study (NBDPS) (1997-2011).
METHODS: We obtained detailed information on maternal occupation during the month before to three months after conception. Expert raters, masked to case-control status, assessed job descriptions to assign categorical levels of exposure. Categories were quantitatively mapped to estimate cumulative exposure to PAHs, incorporating exposure intensity, frequency, work duration, and work hours. Quartiles were generated for cumulative maternal exposure to PAHs. Crude and adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were estimated using unconditional logistic regression for quartiles of PAH exposure and six CHD groupings (e.g. conotruncal) and specific subtypes (e.g. tetralogy of Fallot [ToF]). Final models were adjusted for maternal age, race/ethnicity, education, smoking, anticonvulsant use, folic acid supplementation, and study center.
RESULTS: There were 4,775 case and 7,734 control infants eligible for the study. The prevalence of occupational exposure to PAHs was 10.2% among both case and control mothers. In adjusted analysis, compared to mothers with no occupational PAH exposure, those in the highest quartile of exposure were more likely to have offspring in the conotruncal heart defects group (OR 1.41; 95% CI 1.00-2.00), and with ToF (OR 1.83; 95% CI 1.21-2.78).
CONCLUSIONS: Women in the highest quartile of estimated cumulative occupational PAH exposure during early pregnancy were more likely to have offspring with conotruncal heart defects, specifically ToF, compared to women with no occupational PAH exposure. Other comparisons between PAHs and other CHDs subgroups did not show any statistically precise associations.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Congenital heart defects; Occupational health; Polycyclic aromatic hydrocarbons

Mesh:

Substances:

Year:  2020        PMID: 32335433      PMCID: PMC8756335          DOI: 10.1016/j.envres.2020.109550

Source DB:  PubMed          Journal:  Environ Res        ISSN: 0013-9351            Impact factor:   6.498


  43 in total

1.  Inter-rater reliability of assessed prenatal maternal occupational exposures to solvents, polycyclic aromatic hydrocarbons, and heavy metals.

Authors:  Carissa M Rocheleau; Christina C Lawson; Martha A Waters; Misty J Hein; Patricia A Stewart; Adolfo Correa; Diana Echeverria; Jennita Reefhuis
Journal:  J Occup Environ Hyg       Date:  2011-12       Impact factor: 2.155

2.  Teratogenic effects of benzo[a]pyrene in developing chick embryo.

Authors:  J Anwer; N K Mehrotra
Journal:  Toxicol Lett       Date:  1988-03       Impact factor: 4.372

3.  The National Birth Defects Prevention Study.

Authors:  P W Yoon; S A Rasmussen; M C Lynberg; C A Moore; M Anderka; S L Carmichael; P Costa; C Druschel; C A Hobbs; P A Romitti; P H Langlois; L D Edmonds
Journal:  Public Health Rep       Date:  2001       Impact factor: 2.792

Review 4.  Oxidative DNA damage and repair in teratogenesis and neurodevelopmental deficits.

Authors:  Peter G Wells; Gordon P McCallum; Kyla C H Lam; Jeffrey T Henderson; Stephanie L Ondovcik
Journal:  Birth Defects Res C Embryo Today       Date:  2010-06

5.  Effects of the polycyclic aromatic hydrocarbon heterocycles, carbazole and dibenzothiophene, on in vivo and in vitro CYP1A activity and polycyclic aromatic hydrocarbon-derived embryonic deformities.

Authors:  Deena M Wassenberg; Abby L Nerlinger; Lauren P Battle; Richard T Di Giulio
Journal:  Environ Toxicol Chem       Date:  2005-10       Impact factor: 3.742

6.  Defects in cardiac function precede morphological abnormalities in fish embryos exposed to polycyclic aromatic hydrocarbons.

Authors:  John P Incardona; Tracy K Collier; Nathaniel L Scholz
Journal:  Toxicol Appl Pharmacol       Date:  2004-04-15       Impact factor: 4.219

7.  Biomarkers of exposure to combustion by-products in a human population in Shanxi, China.

Authors:  Ziad Naufal; Li Zhiwen; Li Zhu; Guo-Dong Zhou; Thomas McDonald; Ling Yu He; Laura Mitchell; Aiguo Ren; Huiping Zhu; Richard Finnell; Kirby C Donnelly
Journal:  J Expo Sci Environ Epidemiol       Date:  2009-03-11       Impact factor: 5.563

8.  Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations.

Authors:  Alissa R Caton; Erin M Bell; Charlotte M Druschel; Martha M Werler; Angela E Lin; Marilyn L Browne; Louise-Anne McNutt; Paul A Romitti; Allen A Mitchell; Richard S Olney; Adolfo Correa
Journal:  Hypertension       Date:  2009-05-11       Impact factor: 10.190

9.  Oxidative damage induced by carcinogenic polycyclic aromatic hydrocarbons and organic extracts from urban air particulate matter.

Authors:  Katerina Hanzalova; Pavel Rossner; Radim J Sram
Journal:  Mutat Res       Date:  2010-01-14       Impact factor: 2.433

Review 10.  Urinary 1-hydroxypyrene (1-HP) in environmental and occupational studies--a review.

Authors:  Ase M Hansen; Line Mathiesen; Marie Pedersen; Lisbeth E Knudsen
Journal:  Int J Hyg Environ Health       Date:  2008-01-28       Impact factor: 5.840

View more
  1 in total

Review 1.  Data-Driven Modeling of Pregnancy-Related Complications.

Authors:  Camilo Espinosa; Martin Becker; Ivana Marić; Ronald J Wong; Gary M Shaw; Brice Gaudilliere; Nima Aghaeepour; David K Stevenson
Journal:  Trends Mol Med       Date:  2021-02-08       Impact factor: 15.272

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.